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Anticancer peptideIn this work, we introduce a new customized anti-lung cancer peptide, CB1a, with IC50 of about 25.0±1.6 μM
on NCI-H460 lung cancer cells. Using a multi-cellular tumor spheroid (MCTS) model, results show that CB1a
is potent in preventing the growth of lung cancer tumor-like growths in vitro. Additionally, atomic force mi-
croscopy (AFM) was used to examine cell surface damage of a single cancer. The mechanism for cell death
under CB1a toxicity was veriﬁed as being largely due to cell surface damage. Moreover, with a treatment dos-
age of CB1a at 25 μM, Young's module (E) shows that the elasticity and stiffness of cancer cell decreased with
time such that the interaction time for a 50% reduction of E (IT50) was about 7.0 min. This new single-cell tox-
icity investigation using IT50 under AFM assay can be used to separately verify drug efﬁcacy in support of the
traditional IC50 measurement in bulk solution. These results could be of special interest to researchers en-
gaged in new drug development.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
As natural antibiotics, most antimicrobial peptides (AMPs) have
both cationic and amphipathic properties that allow them to interact
with bacterial cytoplasmic membranes leading to cell death [1–4].
Mutation of these natural AMPs can signiﬁcantly alter bacterial killing
ability. For example, a recent study showed that N-acylated mutant of
LF11 derived from human latoferricin could enhance antimicrobial
activity on Escherichia coli [5]. Some AMPs such as cecropins [6–8],
magainins [9–14], melittins [15–17], human LL-37 [18–23] and host
defense peptides [24,25] have the ability to kill cancer cells. Both
cell-killing mechanisms (antimicrobial and anticancer) may share
similarities such as membranolysis [26–30]. Among these peptides,
melittin is the most toxic to human cells. However, a recent report
[31] showed that if melittin was used to form complexes with nano-
particles, its anti-cancer ability could be enhanced, half-life increased,
and toxicity inmice decreased. These observations imply that under par-
ticular circumstances altering original peptides can make them more
effective in killing cells [30].
Cecropins (such as cecropins A, B, C, D, E and F) belong to a family
of natural antimicrobial peptides composed of 34–39 amino acids ofP, antimicrobial peptide; CB,
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rights reserved.high sequence homology [7,32]. These peptides have common char-
acteristics. They are mostly constructed with α-helical structure at
the amphipathic N-terminal (where one side is hydrophilic and the
other hydrophobic) and the hydrophobic residues of the C-terminal.
Cecropin B (CB) has the strongest antibacterial activity of this family.
Our previous studies have shown that CB can disrupt bacterial mem-
branes and also kill cancer cells including leukemia, stomach carcino-
ma, and lung cancer cells [33–38]. However, the efﬁcacies of CB on
killing cancer cells were not as good as for killing bacteria as compared
with other anti-cancer agents. The possible explanation is that CB
which is naturally good to kill bacteria may not be good to apply it
for killing such as cancer cells where the surface conformations are
different from bacteria's. For the purpose of developing an effective
anti-cancer peptide, therefore, a new design using natural CB's se-
quence as a template is essential. Accordingly, peptide, CB1a, was
constructed by using three-repeated amphiphathic section of the CB
N-terminal (Lys-Trp-Lys-Val-Phe-Lys-Lys-Ile-Glu-Lys or KWKVFKKIEK)
and bridged with Ala-Gly-Pro (or AGP) as: NH2-KWKVFKKIEK-
KWKVFKKIEK-AGP-KWKVFKKIEK-COOH (see Ref. [39] for details).
Nuclear Magnetic Resonance (NMR) structural study showed that
CB1a has two helices kinked (kink angle: 110°) by a bridge, Ala-Gly-Pro
(see RCSB-Protein Data Bank; 2IGR). The advantages in creating CB1a as
a custom anticancer peptide were: (i) Proline involved in the bridge or
kink section as it can be effectively used for oligomerization and pore
gating in the lipid bilayer of cancer cell membranes [40,41]; (ii) The
three repeated amphipathic sections of CB1a allow for high ﬂexibility
to dynamically pass through the cell surface to the cell lipid bilayer;
(iii) The high density of positive charge (net+12)which provides strong
binding capacitywith cancer cellmembranes, which have a high negative
Fig. 1. IC50 measurements of CB1a on lung cancer cell line, NCI-H520. Two measure-
ments were done (CB1a peptides were produced by different batches, CB1a_1 and
CB1a_2, respectively). IC50 of CB1a was about 25.0±1.6 μM. Each point was the average
of ﬁve experimental measurements.
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both the selectivity and toxicity criteria for killing cancer cells [39].
Since CB1a likely kills cancer cells in a similar way as the AMPs
mentioned above i.e., through lipid corruption at the membrane, the
method is described as a physical rather than chemical attack. Chem-
ical attacks describe inhibition of chemical reactions at binding sites
inside the cell such as those for RNA and DNA. Tomeasure the physical
changes in cancer-cell surfaces before and after physical attack by
CB1a, both the elastic force and morphological changes of the cell
membrane were analyzed by atomic force microscopy (AFM). Com-
parisons of stiffness between cancer and normal cells via AFM mea-
surements have been previously reported and conﬁrmed in terms of
clinical concerns about the stiffness of cells, which varies according
to the different mechanical characteristics of membranes [42–48].
Most recently, mechanical stiffness has been correlated with the plasma
membrane potential of vascular endothelial cell using a combination of
ﬂuorescence-based membrane potential recording and AFM-based stiff-
ness measurements [49]. Unlike electron microscopy, AFM does not
require any additional cell-preparation treatments and samples can
be imaged under nearly native conditions with minimal alteration or
damage. Additionally, AFM allows for real-time observation of cell mor-
phological changes.
In this study, we verify the efﬁcacy of CB1a on lung cancer cells
in bulk solution using half maximal inhibitory concentration (IC50)
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay. A multi-cellular tumor spheroid (MCTS) model in test
tubes is also applied to show that CB1a is potent in preventing the
growth of lung cancer tumor-like growths. Furthermore, we identify
the killing pathway for a single cancer cell by observing damage to
the cell surface under AFM measurements. Results show that CB1a
has high selectivity for cancer cells over normal lung cells. While,
doxorubicin (Dox) currently used in clinics does not have high selec-
tivity and causes damage to both normal lung and cancer cells, which
can lead to serious side effects in patients. Since CB1a has both low
toxicity and high selectivity, it may make a good candidate for further
development as an anti-cancer drug.
2. Materials and methods
2.1. Materials
The AFM tip (pointprobe®) was purchased from Nanosensor
(Switzerland). Micro-particle (diameter ~10 μm) was obtained from
Bangs Laboratories (USA). Cell culture media, fetal bovine serum (FBS)
and antibiotics—penicillin and streptomycin were purchased from Gibco
(USA). RPMI-1640 medium, hydrochloride acid, sodium bicarbonate
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) were obtained from Sigma (USA). Doxorubicin was purchased
from Pﬁzer (Italy). Cancer cell lines NCI-H460/NCI-H520 and ﬁbroblast
cell lineMRC-5were purchased from the American Type Culture Collec-
tion (ATCC; USA). Water used was de-ionized and distilled.
2.2. Preparation of peptides
Both CB1a and CB peptides were solid-phase synthesized by
peptide synthesizer (Applied Biosystem Inc.) [50]. Fmoc (9-
ﬂuorenylmethyloxycarbonyl) and HBTU (O-benzotriazole-N,N,N′,
N′-tetramethyl-uronium-hexaﬂuoro-phosphate)/HOBT (N- hy-
droxybenzotriazole) were used as protection and coupling reagents,
respectively. Final products were de-protected and cleaved from the
peptide resin using a solution containing tri-ﬂuoroacetic acid (TFA),
water, phenol, thioanisole and ethanedithiol. The remaining resin was
removed by ﬁltration and the peptides precipitated with diethyl ether
after the organic solvents had evaporated. The crude peptides were
desalted on Sephadex G-10 (20% acetic acid) and puriﬁed by reverse
phase high pressure liquid chromatography (HPLC) (Vydac C-18column, 0.1% TFA in H2O-acetonitrile). Product purities were deter-
mined by HPLC and found to be 95% and 96% for CB1a and CB, respec-
tively. Molecular weights (MWs) of the peptides were determined by
mass spectrometry and found to be almost identical to the theoretical
values (Both observed/calculated MWs (g/mol) are 4191.2/4190.3 and
3834.8/3836.0 for CB1a and CB, respectively). Concentrations of pep-
tideswere determined from thenetweight of peptides and theirmolec-
ular masses (the weight of associated counter ions was not taken into
consideration).
2.3. Cell culture and cytotoxicity assays
Lung cancer cell lines (NCI-H460 and NCI-H520) were grown in
RPMI-1640 culture media supplemented with 10% FBS and 1%
penicillin–streptomycin (PS) antibiotic mixture. Lung ﬁbroblast cell
line (MRC-5) was cultured in MEM medium containing 10% FBS and
1% PS mixture. The above cell lines were cultured at 37 °C in a 5% CO2
humidiﬁed incubator.
The cell suspensions were adjusted to contain 1×105cells/ml be-
fore they were transferred into a 96-well plate (90 μl/well). Each
well was then mixed with 10 μl of peptide solution of different concen-
trations (0, 1, 5, 10, 15, 20, 30, 50, 100 and 200 μM) and each sample col-
lected in triplicate. After 24 h incubation, aMTT-based colorimetric assay
was conducted by adding 40 μl MTT (2 mg/ml)/100 μl DMSO into each
well at room temperature for 10 min (MTT can bemetabolized bymito-
chondrial de-hydrogenases in metabolically active cells to form a
formazan salt with strong absorption at 570 nm (A570 nm)). A570 nm of
each well sample was measured using a Bio-Rad model 450 microtiter
plate reader. Cell survival rate (%) was determined by (ΔA570 nm/
A′570 nm)×100, where ΔA570 nm=A″570 nm−A′570 nm, A′570 nm is the
sample's absorbance without addition of peptide, and A″570 nm is
sample's absorbance with the addition of peptide. IC50 (half maximal
inhibitory concentration) was obtained from the plot of survival rates
(%) vs. peptide concentrations. An illustration of IC50 measurement for
CB1a at different batch productions (CB1a_1 and CB1a_2) is shown in
Fig. 1.
2.4. Multi-cellular tumor spheroid culture
Multi-cellular tumor spheroids (MCTS) of NCI-H460 cancer cells
were constructed on non-adhesive, bacterial culture-grade polystyrene
Fig. 3. Calculation of E. Typical examples of F vs. δ for single cancer cell (NCI-H460)
treated with CB1a (25 μM) were shown at time (A) 5 min and (B) 19 min after AFM
tip approached the cell surface. Fitting lines are shown in bold.
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500 single cells at a density of 3×104cells/mlwere deposited as drops on
the lids of 90-mm Petri dishes to generate cellular aggregates. Lids with
droplets attached were inverted over dishes ﬁlled with 10-ml PBS and
incubated at 37 °C in a 5% CO2 incubator. NCI-H460 cancer cells were
de-attached andMCTS were then obtained: (i) without CB1a treatment;
(ii)with immediate CB1a treatment; (iii) post 30 min of CB1a treatment.
2.5. Cell images
Cell (NCI-H460 lung cancer cell andMRC-5 normal lung cell) dam-
age induced by CB1a was observed by AFM (NanoWizard BioAFM,
JPK, Germany) at a resolution of 512×512 pixels. A silicon-made AFM
tip (NanoWorld, Switzerland) with a spring constant of 0.02 N/m was
used for cell surface imaging measurement. After drug (CB1a or Dox)
treatment, the medium was removed and the remaining sample
washed by 1× PBS solution at pH 7.2. The desired cell was then ﬁxed
by 4% paraformaldehyde at room temperature for 10 min. The sample
was rinsed again by 1X PBS buffer, water, and then air dried. The details
of the set-up procedures for AFM to obtain cell morphology or me-
chanical property changes are shown in Appendix. Typical examples
of “single cell” images (topology image and 3D conﬁguration) by AFM
tip are shown in Fig. 2.
2.6. Young's modulus (E) measurement
A polystyrene bead (diameter ~10 μm) was attached to the AFM tip
by epoxy resin. The spring constant (0.04 N/m) of the bead-attached
cantileverwas calibrated in the cell culturemediumby forcemodulation
mode. All experiments were done within 30 min to insure living cells.
Young's modulus, E, on the cell was determined by ﬁtting a simpliﬁed











where F is an applied external force, R is radius of tip, δ is the indentation
depth of sample, which can be calculated by δ=h−d, where h is an
indented piezo height and d is distance of cantilever's deﬂection. ν is
Poisson's ratio (0.5 was used for soft biological sample). E is Young's
modulus obtained after ﬁtting with F vs. δ curve. An illustration of
obtaining E on a single cancer cell after treatment with CB1a is shown
in Fig. 3 (ﬁtting curves are shown in bold). In these examples, Es were
760 pa and 119 pa for tip interaction time with the cell surface at 5 min
and 19 min, respectively. Detailed results are given in the “Results” sec-
tion below.Fig. 2. Typical AFMmorphological observations for single cancer cell. (A) AFM tip approache
dimensions of “width” and “length” of cell and the scale shown in the corner between X- and
output is 40 (width)×40 (length) μm with height of 0–1.2 μm.3. Results
3.1. Anti-cancer activity assays and multi-cellular tumor spheroids
Cytotoxicity assays of agents including CB, CB1a and Dox were
done on lung cancer and normal lung cells. IC50s of these compoundss cancer cell; (B) cell topology image; (C) cell 3D conﬁguration. X- and Y-axis are for the
Y-axis indicates the “height” of cell. For NCI-H460 cell, the dimension conﬁned in AFM
Table 1
IC50s of CB, CB1a and DOX on lung cancer and normal lung cells.
IC50 (μM) Lung cancer cells Normal lung cell
NCI-H460 NCI-H520 MRC-5
CB >200 58.8±2.0 >100
CB1a 25.0±1.6 22.7±1.2 >100
Dox 18.4±0.8 18.0±1.0 16.6±1.4
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lung cancer cells (25.0±1.6 μM for NCI-H460 and IC50=22.7±
1.2 μM for NCI-H520) and equally higher IC50 on normal lung cells
(IC50>100 μM for MRC-5). This implies that CB1a is outstandingly cy-
totoxic to lung cancer cells while not being seriously harmful to nor-
mal lung cells. For Dox, although it has lower IC50s on both lung
cancer cell lines (18.4±0.8 μM and 18.0±1.0 μM for NCI-H460 and
NCI-H520, respectively), the IC50 on normal lung cells is even lower
(only 16.6±1.4 μM for MRC-5). In other words, Dox is more toxic
to normal lung cells than abnormal cells with the potential for caus-
ing serious side-effects in cancer patients. Compared with Dox, CB1a
seems to have much higher selectivity for lung cancer cells over nor-
mal lung cells.
In addition to in vitro toxicity testing of CB1a on cancer and normal
cells above, further efﬁcacy investigation of this peptide on cancer
cell-aggregated tumor-like growths was identiﬁed by ex vivo MCTS
modeling. In this case, NCI-H460 cancer cells were de-attached and
MCTS were then obtained: (i) without CB1a treatment; (ii) with im-
mediate CB1a treatment; (iii) post 30 min of CB1a treatment. Fig. 4A
to C shows the respective results of the three different tumor growth
scenarios. In Fig. 4A, a complete solid tumor-like growth formed when
NCI-H460 cancer cells were added into a test tube. Fig. 4B shows a de-
graded tumor if CB1a peptide was added simultaneously to the test
tube along with the cancer cells. Fig. 4C shows that only small spots
formed in the test tube if CB1a peptide was added 30 min in advance
of cell seeding. This result indicates that CB1a damages cancer cells
and prevents cell–cell interaction/aggregation and consequently inter-
rupts tumor-like growth.
3.2. AFM observations for single normal lung cell, MRC-5, treated with
CB1a and Dox
(1) CB1a effect: AFM 3D images of single normal lung cell, MRC-5,
under CB1a (25 μM) treatment at time 0, 0.5, 2, 8, 16 and 24 h
are shown in Fig. 5A to F, respectively. For different incubationFig. 4. Spheroidal tumor-like growth formed by NCI-H460 cancer cells in test tube. (A) tum
CB1; (C) tumor formed with pre-addition of CB1a by 30 min. Concentration of CB1a was 25
24 h.times, the cell nucleus (raised area in white) can be seen in
each ﬁgure. This is consistent with no signiﬁcant morphological
change, indicating MRC-5 remained healthy for the times of the
experiment; i.e., CB1a did not cause obvious injury to a normal
lung cell during the 24 h test period.
(2) Dox effect: Healthy MRC-5 cell was observed after dosing with
18 μM Dox at 2 h; 8 h; 16 h and 24 h and the results shown in
Fig. 6A to D. By 8 h the cell had become ﬂatter, by 16 h the cell
nucleus had begun to breakdown and by 24 h the cell had
completely collapsed. These results show that Dox is toxic to a
normal lung cell within 8 h.3.3. AFM observations for single lung cancer cell treated with CB1a
Cytotoxicity effects of CB1a on single human lung cancer cells,
NCI-H460 and NCI-H520, were done by AFM observations. A cellular
surface image of NCI-H460 without CB1a treatment is shown in
Fig. 7A. The cell shape is smooth and round (diameter ~35 μm) and
it has a distinctive contour marking the nucleus. A similar observation
for NCI-H520 without treatment with CB1a was obtained (see Fig. 7D).
Treatments with CB1a at different concentrations of 25 and 50 μMwere
done on two cell lines for 30 min. Results show that these single cells
became sunken and appeared to have irregular shapes or ragged cellu-
lar conﬁgurations (see Fig. 7B and C for NCI-H460 and Fig. 7E and F for
NCI-H520). These results indicate CB1a is highly toxic to cancer cells
within 30 min.
3.4. Single cell surface damage determined by Young's modulus (E)
The physical changes in the properties of cell surface induced by
CB1a are given by real-time measurement of E for a CB1a-treated sin-
gle cell. Plots of normalized Young's modulus E vs. time are shown in
Fig. 8. Without CB1a treatment, E of NCI-H460 cell remained at about
1.0 (Fig. 8A) within 25 min. After the addition of 12.5 μM CB1a, the
level of E gradually declined to about 0.62 by 30 min (Fig. 8B). These
results indicate CB1a's effects on cell surface. However, the shape of
the line is still similar to that of Fig. 8A; i.e., almost ﬂat. The shape of
the E line vs. time changes when the concentration of CB1a's increases
to 25 μM. This result is similar to that of IC50 (see Fig. 1). E drops in a
reverse parabolic contour to about only 35% within 10 min. To give
the expression of E physical meaning, a new term IT50 is deﬁned in
this work. It indicates interaction time (IT) whereby E is reduced by
50%. Accordingly, IT50s of CB1a on NCI-H460 were 7.0 min at 25 μM
(see Fig. 8C) and 4.8 min at 50 μM (see Fig. 8D). Furthermore, E for
CB1a-treated MRC-5 normal lung cell was also investigated. Plots of
normalized E vs. time for CB1a at 5 and 25 μM are shown in Fig. 9Aor formed without addition of CB1a; (B) tumor formed with simultaneous addition of
μM and initial cancer cell concentration was 2×103 cells. All photos were taken after
Fig. 5. AFM images of MRC-5 cell treated with CB1a (25 μM) at (A) 0 h; (B) 0.5 h; (C) 2 h; (D) 8 h; (E) 16 h and (F) 24 h. Since both cellular size and shape of MRC-5 cell are ir-
regular, a ﬁxed area (70×70 μm) was conﬁned and detected. The raised area in white in each ﬁgure is about 12 μm in width and 20–25 μm in length.
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and IT50s were inﬁnite. These results indicate no changes to the phys-
ical condition of the normal lung cell under treatment with CB1a at
25 μM within 30 min.
4. Discussion
Therapeutic drugs work via chemical or physical pathways in the
treatment of cancer cells. A physical attack on a cancer cell is one
where cellular membranes are compromised leading to cell death.Fig. 6. AFM images (70×70 μm) of MRC-5 treated with DoUnderstanding the mechanism of cellular death is essential for the
development of peptides as anticancer drugs. This paper investigates
a customized peptide from the CB group, CB1a, to see how cell dam-
age occurs in a single cell by AFM microscopic observations and test
the efﬁcacy and selectivity of CB1a against lung cancer cells. Before
the single cell measurements, general investigations of IC50 for CB1a
on lung cancer and normal lung cells via MTT assay were performed.
We used the current clinically available drug, Dox, as a reference com-
pound. Based on the results of MTT assay, CB1a has high selectivity for
lung cancer cells over normal cells. Its selectivity was much better thanx (18 μM) at (A) 2 h; (B) 8 h; (C) 16 h and (D) 24 h.
Fig. 7. AFM images (40×40 μm) of NCI-H460 and NCI-H520 treated with CB1a peptide. (A), (B) and (C) are of NCI-H460 cell and (D), (E) and (F) are of NCI-H520 cell treated with
CB1a at 0 μM (A, D); 25 μM (B, E) and 50 μM (C, F), respectively. Incubation time is 30 min.
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mal lung cells to that of lung cancer cells) is larger than 15 on average,
while, SI of Dox is mostly less than 1 (data not shown). Further evidence
of CB1a's efﬁcacy on lung cancer cells was obtained using MCTS model-
ing. Results indicated that CB1a had the ability to prevent lung cancer
cells (NCI-H460) from forming tumor-like growths in test tubes. MCTS
modeling gives guidance on the aggregation of cancer cells under grav-
ity whereby cell–cell interactions are the main force allowing for cellFig. 8. Real timemeasurements of Young'smodulus for single NCI-H460 cell. Cellwas treatedw
of E shown in each ﬁgure is done for each data set at different times (0−30 min) divided by t
representative cells per each AFM experiment. The symbolic arrows shown in ﬁgs. (C) and (Daggregations to occur in solution. Under these circumstances, if cancer
cell surfaces are not viable (compromised by physical attack from
CB1a) they cannot interact with healthy cancer cell surfaces and aggre-
gation is partially inhibited or cannot occur. This is shown in Fig. 4B and
C for addition of CB1a at the time of seeding with cancer cells and
30 min prior to seeding, respectively. The example of adding CB1a to so-
lution 30 min prior to seeding with cancer cells may tell us something
of how thismechanismworks. If cancer cell surfaces aremore efﬁcientlyith CB1a at (A) 0 μM; (B) 12.5 μM; (C) 25 μMand (D) 50 μMwithin 30 min. Normalization
he original data at time zero. The results with standard deviations were done by using 10
) indicated the IT50s, which were 7.0 min and 4.8 min, respectively.
Fig. 9. Real time measurements of Young's modulus for single MRC-5 normal lung cell.
Cell was treated with CB1a at (A) 5 μM and (B) 25 μM for no more than 30 min. The
results with standard deviations were done by using 10 representative cells per each
AFM experiment.
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with healthy cancer cells and aggregation is prevented (Fig. 4C). Dose
dependence of CB1a on MCTS is further evidence of this (data not
shown). These results could provide a future model for animal tests
with peptide injections done in advance of the introduction of cancer
cells. From a clinical point of view, if tolerated and deliverable, CB1a
peptide could be used in early stage treatments or post surgery treat-
ments when cancer cells are not so abundant. Furthermore, CB1a
shows promise because of its high selectivity for cancer cells and
low damage to normal lung cells (MRC-5, under CB1a (25 μM) at
time=24 h showed no obvious damage to cells, see Fig. 5F). CB1a's
unique toxicity characteristics for normal tissue vs. cancerous tissue
may be more favorable than those clinical drugs used for curing lung
cancer.
The evidence of CB1a's efﬁcacy in killing cancer cells in vitromade
investigating the mechanism at a cellular level worthwhile. Current
cancer drug Dox was again used as a reference compound. Morpho-
logical change of the cell surface during treatment with both drugs
was investigated in real time using AFM. The study shows very different
results for CB1a and Dox on normal lung cell, MRC-5. For Dox dosage of
18 μM, the normal cell's nucleus collapsed after an incubation time of
8 h. However, there was no evidence of damage to either the nucleus
or cell as a whole under CB1a at 25 μM even after 24 h (see Fig. 5).
Meanwhile, cancer cells NCI-H460 and NCI-H520 treated with CB1a at
25 μM showed considerable cellular breakdown after only 30 min
(see Fig. 7). Clearly, CB1a is highly toxic to cancer cells, but has low
toxicity toward normal cells. Consequently, we think CB1a hasmany fa-
vorable characteristics as a chemotherapeutic drug.Further evidence of the mechanism by which CB1a kills cancer
cells is provided by studying the changes in a cell's physical proper-
ties. Healthy cells have elastic properties. Under pressure (for exam-
ple, from the external force applied by an AFM tip) a cell's shape
becomes deformed but once the force is removed it will spring back
to its original shape. However, if the cell surface is damaged (or mem-
brane broken) by a drug like CB1a peptide, the cell loses its elasticity
and this can be observed as a function of time. This work is the ﬁrst of
its kind to show cell degradation caused by CB1a and its direct rela-
tionship with elasticity change (or Young's modulus, E, change). The
results conﬁrmed that E reduced as a function of time when CB1a
peptide was added to cancer cells. However, when CB1a was added
to normal cells, E was almost a constant with time. This paper pro-
poses that a new measure of drug efﬁcacy IT50 be used in standard
operating procedures (SOP) for future drug veriﬁcation. IT50 is the in-
teraction time between drug and target cell whereby E is reduced by
50%. Compared to the current standard IC50, IT50 can be used as a
measure at the single cell level over time whereas IC50 looks at bulk
solutions. For example, for CB1a-treatedNCI-H460 cancer cell, a reversed
parabolic curve of E vs. timewas obtained at 25 μM(see Fig. 8C)with IT50
of about 7.0 min. The IC50 of CB1a was 25 μM. Both IT50 (7.0 min) and
IC50 (25 μM) can therefore be considered as cross veriﬁcation for drug
efﬁcacy in in vitro investigations.
Dox uses a chemical pathway to kill cells through interaction with
DNA by intercalation and inhibition of macromolecular biosynthesis
[53,54]. The time needed to complete this inhibition action in cells
leading cell to death for Dox may be longer (several hours) than CB1a
requires to do physical damage to cancer cells (only about 20 min).
The quickness with which CB1a kills cells may be explained by our pre-
vious results that CB1a peptide ﬁrst binds with cancer cell surfaces
through heparin-like binding and is then forced into the lipidmembrane
by hydrophilic and hydrophobic interactions with lipid heads and tails,
respectively [39].
5. Conclusions
A customized anticancer peptide, CB1a, is shown to have high toxic-
ity against lung cancer cells NCI-H460 and NCI-H520. It is also shown to
be highly selective for these cells over normal lung cells, MRC-5. These
two qualities suggest CB1a would make a good candidate for drug de-
velopment. Additionally, the paper presents a newmethod for measur-
ing drug efﬁcacy IT50—interaction time between drug and target cell
whereby Young's Modulus E is reduced by 50%. For these experiments,
CB1a has been shown to be potent against lung cancer cells with an IC50
of 25 μM and IT50 of 7.0 min. The cell death time was very quick and
could be observed in real-time by AFM measurement. If compounds
kill cells by a physical attachmechanism, IT50may be an efﬁcient meth-
od for verifying drug efﬁcacy.
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Appendix A
AFM set-up for cell observation by microscope was shown below
diagram. Sample showing cell surface and inside of cell (in light and
dark reds, respectively) viewed by light microscope. AFM tip was
properly adjusted to touch the cell. Upon scanning the cell by tip,
the interaction force between the tip and cell surface causes a deﬂection.
This deﬂection can be identiﬁed by a shift in the laser beamwhich is de-
tectable by a quadrant photodiode. During data processing, all electric
signals are transformed into either height (μm) or force (N) and both a
topographic image and force relationship curve could be obtained (see
right-side ﬁgures).
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